Literature DB >> 11745408

Inhibition of neuroblastoma-induced angiogenesis by fenretinide.

D Ribatti1, G Alessandri, M Baronio, L Raffaghello, E Cosimo, D Marimpietri, P G Montaldo, G De Falco, A Caruso, A Vacca, M Ponzoni.   

Abstract

Retinoids are a class of natural or synthetic compounds that participate in the control of cell proliferation, differentiation and fetal development. The synthetic retinoid fenretinide (HPR) inhibits carcinogenesis in various animal models. Retinoids have also been suggested to be effective inhibitors of angiogenesis. The effects of HPR on certain endothelial cell functions were investigated in vitro, and its effects on angiogenesis was studied in vivo, by using the chorioallantoic membrane (CAM) assay. HPR inhibited vascular endothelial growth factor- (VEGF-) and fibroblast growth factor-2- (FGF-2)-induced endothelial cell proliferation without affecting endothelial motility; moreover, HPR inhibited growth factor-induced angiogenesis in the CAM assay. Furthermore, a significant antiangiogenic potential of HPR has also been observed in neuroblastoma (NB) biopsy-induced angiogenesis in vivo. We previously demonstrated that supernatants derived from NB cell lines stimulated endothelial cell proliferation. In the present study, we found that this effect was abolished when NB cells were incubated in the presence of HPR. VEGF- and FGF-2-specific ELISA assays, performed on both NB cells derived from conditioned medium and cellular extracts, indicated no consistent effect of HPR on the level of these angiogenic cytokines. Moreover, RT-PCR analysis of VEGF and FGF-2 gene expression confirmed the above lack of effect. HPR was also able to significantly repress the spontaneous growth of endothelial cells, requiring at least 48-72 hr of treatment with HPR, followed by a progressive accumulation of cells in G(1) at subsequent time points. Finally, immunohistochemistry experiments performed in the CAM assay demonstrated that endothelial staining of both VEGF receptor 2 and FGF-2 receptor-2 was reduced after implantation of HPR-loaded sponges, as compared to control CAMs. These data suggest that HPR exerts its antiangiogenic activity through both a direct effect on endothelial cell proliferative activity and an inhibitory effect on the responsivity of the endothelial cells to the proliferative stimuli mediated by angiogenic growth factors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745408     DOI: 10.1002/ijc.1441

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 2.  The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.

Authors:  Logan C DeBord; Ravi R Pathak; Mariana Villaneuva; Hsuan-Chen Liu; Daniel A Harrington; Wendong Yu; Michael T Lewis; Andrew G Sikora
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.

Authors:  Judith G Villablanca; Wendy B London; Arlene Naranjo; Patrick McGrady; Matthew M Ames; Joel M Reid; Renee M McGovern; Sarah A Buhrow; Hollie Jackson; Enno Stranzinger; Brenda J Kitchen; Paul M Sondel; Marguerite T Parisi; Barry Shulkin; Gregory A Yanik; Susan L Cohn; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

4.  The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.

Authors:  Roberto Benelli; Stefano Monteghirfo; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

5.  Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Authors:  Barry J Maurer; Min H Kang; Judith G Villablanca; Jitka Janeba; Susan Groshen; Katherine K Matthay; Paul M Sondel; John M Maris; Hollie A Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Beth Hasenauer; C Patrick Reynolds; Araz Marachelian
Journal:  Pediatr Blood Cancer       Date:  2013-06-29       Impact factor: 3.167

6.  Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts.

Authors:  S Karmakar; S Roy Choudhury; N L Banik; S K Ray
Journal:  Neuroscience       Date:  2009-06-18       Impact factor: 3.590

7.  The CAM Assay as an Alternative In Vivo Model for Drug Testing.

Authors:  Regine Schneider-Stock; Domenico Ribatti
Journal:  Handb Exp Pharmacol       Date:  2021

8.  Targeting angiogenesis for controlling neuroblastoma.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  J Oncol       Date:  2011-08-25       Impact factor: 4.375

9.  N-(4-Hydroxyphenyl) Retinamide Potentiated Anti-tumor Efficacy of Genistein in Human Ewing's Sarcoma Xenografts.

Authors:  Surajit Karmakar; Subhasree Roy Choudhury; Naren L Banik; Swapan K Ray
Journal:  World J Oncol       Date:  2011-04

10.  The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

Authors:  Sarah B Whittle; Kalyani Patel; Linna Zhang; Sarah E Woodfield; Michael Du; Valeria Smith; Peter E Zage
Journal:  Invest New Drugs       Date:  2016-09-01       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.